What this means
A trial gave people weekly rapamycin or a placebo for 48 weeks and checked side effects and blood tests. Some measures improved in certain groups, but the researchers say more work is needed.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- Healthy adults in a 48-week trial with placebo and two doses
- Kind of research
- A clinical trial in people
The science
- Original title
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.
- Authors
- Moel M, Harinath G, Lee V et al.
- Journal
- Aging
- Published
- Apr 6, 2025
- Study type
- Clinical trial · in humans
- PMID
- 40188830 ↗
Abstract
What they did
This 48-week decentralized, double-blinded, randomized, placebo-controlled trial (NCT04488601) evaluated the long-term safety of intermittent low-dose rapamycin in a healthy, normative-aging human cohort. Participants received placebo, 5 mg or 10 mg compounded rapamycin weekly. The primary outcome measure was visceral adiposity (by DXA scan), secondary outcomes were blood biomarkers, and lean tissue and bone mineral content (by DXA scan). Established surveys were utilized to evaluate health and well-being. Safety was assessed through adverse events and blood biomarker monitoring.
What they found
Adverse and serious adverse events were similar across all groups. Visceral adiposity did not change significantly (ηp2 = 0.001, p = 0.942), and changes in blood biomarkers remained within normal ranges. Lean tissue mass (ηp2 = 0.202, p = 0.013) and self-reported pain (ηp2 = 0.168, p = 0.015) improved significantly for women using 10 mg rapamycin. Self-reported emotional well-being (ηp2 = 0.108, p = 0.023) and general health (ηp2 = 0.166, p = 0.004) also improved for those using 5 mg rapamycin. No other significant effects were observed. Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan metrics for longevity, and will aim to more comprehensively establish efficacy.
The authors' abstract, grouped under plain headings from its own section labels.
Moel M, Harinath G, Lee V et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging. 2025. doi:10.18632/aging.206235. PMID: 40188830. https://pubmed.ncbi.nlm.nih.gov/40188830/
Related research
Copper and iron help yeast cells survive in different ways
Researchers studied yeast cells that were short on food. Copper and iron both helped cells survive, but through different cell signals. This is early lab work, so it does not show what happens in people.
A review proposes a link between two brain proteins and aging-related memory loss
This review looks at two brain proteins that help control inhibitory connections between nerve cells. It suggests they may work together in brain aging, but this idea is not yet proven.
See all research on Rapamycin →